Drug sponsors remain hopeful for regulatory reform in India following US NIH cut-back on trials
This article was originally published in SRA
Executive Summary
In what is probably one of its more lucid responses on the recent scrapping of a large number of clinical studies in India, the US National Institutes of Health (NIH), the largest source of funding for medical research in the world, has said that the Indian trials it stopped were mainly because of the country's evolving trial regulations1.
You may also be interested in...
India To Scrap Intellectual Property Appellate Board
Legal experts explain why India’s plans to abolish the Intellectual Property Appellate Board and shift its powers to courts may be problematic for stakeholders, including those pursuing infringement charges. The transition could mean a significant burden on courts both in terms of capability and capacity, and IPR cases will now conflate into all other pending commercial matters, some experts said, though others cheered the proposed change.
Creating Healthcare Unicorns: Ex-Novartis CFO Shares Secret Sauce
Ex-Novartis executive and co-founder of investment bank MM Dillon & Co shares insights around where healthcare unicorns can be found and some core criteria to build such firms.
India To Scrap Intellectual Property Appellate Board: Should Pharma Worry?
Legal experts tell the Pink Sheet why India’s plans to abolish the Intellectual Property Appellate Board and shift its powers to courts may be problematic for stakeholders, including those pursuing infringement charges. The transition could mean a significant burden on courts both in terms of capability and capacity, and IPR cases will now conflate into all other pending commercial matters, some experts said, though others cheered the proposed change.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: